Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Supply chain

Government spends £87m on contracts to deliver extra freight capacity for no-deal Brexit

A DFDS ferry at Dover

Source: Shutterstock.com

The Department for Transport has signed six-month contracts with Brittany Ferries, DFDS, P&O and Stena Line for transporting goods, including medicines

The government has signed contracts with four transport companies worth £87m in total, which it says will help to ensure the continued supply of medicines.

The Department for Transport (DfT) announced on 11 October 2019 that it had signed the six-month contracts with Brittany Ferries, DFDS, P&O and Stena Line for the mass transportation of category 1 goods, which includes medicines. 

The DfT said these contracts are different to those tendered in July 2019 by the Department of Health and Social Care worth £25m.

In a statement, the DfT said the ferries would be expected to operate on routes that the government said are less likely to face any potential disruption if the UK leaves the EU without a deal on 31 October 2019.

Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry, said the added capacity “gives companies valuable extra detail to help finalise their plans for a ‘no-deal’ Brexit”.

The contracts come as a report published by Public Health Wales, ‘The public health implications of Brexit in Wales: a health impact assessment approach’, warned that “there could be population groups who potentially will be adversely affected by Brexit in a multifaceted, cumulative way”.

The report, which was published on 11 September 2019, said that older people, people with chronic conditions or disabilities requiring access to health and social care services, and people on lower incomes “will be more susceptible to any negative effects of Brexit”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207195

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.